|
1
|
Cronin KA, Lake AJ, Scott S, Sherman RL,
Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et
al: Annual report to the nation on the status of cancer, part I:
National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao F, Shen J, Yuan Z, Yu X, Jiang P,
Zhong B, Xiang J, Ren G, Xie L and Yan S: Trends in treatment for
prostate cancer in china: Preliminary patterns of care study in a
single institution. J Cancer. 9:1797–1803. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang Y, Jiang X, Liang X and Jiang G:
Molecular and cellular mechanisms of castration resistant prostate
cancer. Oncol Lett. 15:6063–6076. 2018.PubMed/NCBI
|
|
5
|
Mottet N, Bellmunt J, Bolla M, Joniau S,
Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F
and Heidenreich A: EAU Guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol. 59:572–583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Summers N, Vanderpuye-Orgle J, Reinhart M,
Gallagher M and Sartor O: Efficacy and safety of post-docetaxel
therapies in metastatic castrate-resistant prostate cancer: A
systematic review of the literature. Curr Med Res Opin.
33:1995–2008. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seitz AK, Thoene S, Bietenbeck A, Nawroth
R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, et
al: AR-V7 in peripheral whole blood of patients with
castration-resistant prostate cancer: Association with
treatment-specific outcome under abiraterone and enzalutamide. Eur
Urol. 72:828–834. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berthold DR, Pond GR, Roessner M, de Wit
R, Eisenberger M and Tannock AI; TAX-327 investigators, : Treatment
of hormone-refractory prostate cancer with docetaxel or
mitoxantrone: Relationships between prostate-specific antigen,
pain, and quality of life response and survival in the TAX-327
Study. Clin Cancer Res. 14:2763–2767. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao Y, Huang H, Chen C, Liu H, Liu H, Su
F, Bi J, Lam TB, Li J, Lin T and Huang J: Efficacy and safety of
different interventions in castration resistant prostate cancer
progressing after docetaxel-based chemotherapy: Bayesian network
analysis of randomized controlled trials. J Cancer. 9:690–701.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hongo H, Kosaka T and Oya M: Analysis of
cabazitaxel-resistant mechanism in human castration-resistant
prostate cancer. Cancer Sci. 109:2937–2945. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yun EJ, Lo UG and Hsieh JT: The evolving
landscape of prostate cancer stem cell: Therapeutic implications
and future challenges. Asian J Urol. 3:203–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Faivre EJ, Wilcox D, Lin X, Hessler P,
Torrent M, He W, Uziel T, Albert DH, McDaniel K, Kati W and Shen Y:
Exploitation of castration-resistant prostate cancer transcription
factor dependencies by the novel BET inhibitor ABBV-075. Mol Cancer
Res. 15:35–44. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu J, Sun C, Wang L, Xu M, Zang Y, Zhou
Y, Liu X, Tao W, Xue B, Shan Y and Yang D: Targeting survivin using
a combination of miR-494 and survivin shRNA has synergistic effects
on the suppression of prostate cancer growth. Mol Med Rep.
13:1602–1610. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu J, Wang S, Zhang W, Qiu J, Shan Y,
Yang D and Shen B: Screening key microRNAs for castration-resistant
prostate cancer based on miRNA/mRNA functional synergistic network.
Oncotarget. 6:43819–43830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang DR, Ding XF, Luo J, Shan YX, Wang R,
Lin SJ, Li G, Huang CK, Zhu J, Chen Y, et al: Increased
chemosensitivity via targeting testicular nuclear receptor 4
(TR4)-Oct4-Interleukin 1 receptor antagonist (IL1Ra) axis in
prostate cancer CD133+ Stem/progenitor cells to battle prostate
cancer. J Biol Chem. 288:16476–16483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and
Shao ZM: MicroRNA-200a confers chemoresistance by antagonizing
TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 18:742018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu G, Jia B, Cheng Y, Zhou L, Qian B, Liu
Z and Wang Y: MicroRNA-429 sensitizes pancreatic cancer cells to
gemcitabine through regulation of PDCD4. Am J Transl Res.
9:5048–5055. 2017.PubMed/NCBI
|
|
18
|
Puhr M, Hoefer J, Schäfer G, Erb HH, Oh
SJ, Klocker H, Heidegger I, Neuwirt H and Culig Z:
Epithelial-to-mesenchymal transition leads to docetaxel resistance
in prostate cancer and is mediated by reduced expression of
miR-200c and miR-205. Am J Pathol. 181:2188–2201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang
SL, Dai B, Zhu YP, Shen YJ, Shi GH and Ye DW: Serum miRNA-21:
Elevated levels in patients with metastatic hormone-refractory
prostate cancer and potential predictive factor for the efficacy of
docetaxel-based chemotherapy. Prostate. 71:326–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rokhlin OW, Scheinker VS, Taghiyev AF,
Bumcrot D, Glover RA and Cohen MB: MicroRNA-34 mediates
AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol
Ther. 7:1288–1296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gov E and Arga KY: Interactive cooperation
and hierarchical operation of microRNA and transcription factor
crosstalk in human transcriptional regulatory network. IET Syst
Biol. 10:219–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li H, Rokavec M, Jiang L, Horst D and
Hermeking H: Antagonistic Effects of p53 and HIF1A on microRNA-34a
regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to
mesenchymal transition in colorectal cancer cells.
Gastroenterology. 153:505–520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang TH, Tsai MF, Gow CH, Wu SG, Liu YN,
Chang YL, Yu SL, Tsai HC, Lin SW, Chen YW, et al: Upregulation of
microRNA-137 expression by Slug promotes tumor invasion and
metastasis of non-small cell lung cancer cells through suppression
of TFAP2C. Cancer Lett. 402:190–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mcmanus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao L, Yang Y, Xu H, Liu R, Li D, Hong H,
Qin M and Wang Y: MiR-335 functions as a tumor suppressor in
pancreatic cancer by targeting OCT4. Tumour Biol. 35:8309–8318.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kilkenny C, Browne WJ, Cuthill IC, Emerson
M and Altman DG: Improving bioscience research reporting: The
ARRIVE guidelines for reporting animal research. PLoS Biol.
8:e10004122010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qiu X, Zhu J, Sun Y, Fan K, Yang DR, Li G,
Yang G and Chang C: TR4 nuclear receptor increases prostate cancer
invasion via decreasing the miR-373-3p expression to alter
TGFβR2/p-Smad3 signals. Oncotarget. 6:15397–15409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sachdeva M, Zhu S, Wu F, Wu H, Walia V,
Kumar S, Elble R, Watabe K and Mo YY: p53 represses c-Myc through
induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA.
106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin R, Zhang S, Wu Y, Fan X, Jiang F,
Zhang Z, Feng D, Guo X and Xu L: microRNA-145 suppresses lung
adenocarcinoma-initiating cell proliferation by targeting OCT4.
Oncol Rep. 25:1747–1754. 2011.PubMed/NCBI
|
|
31
|
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR-145. Int J Oncol. 42:1473–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao L, Li C, Shen S, Yan Y, Ji W, Wang J,
Qian H, Jiang X, Li Z, Wu M, et al: OCT4 increases BIRC5 and CCND1
expression and promotes cancer progression in hepatocellular
carcinoma. BMC Cancer. 13:822013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang M, Latham DE, Delaney MA and
Chakravarti A: Survivin mediates resistance to antiandrogen therapy
in prostate cancer. Oncogene. 24:2474–2482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao M, Guo L, Wang H, Huang J, Han F,
Xiang S and Wang J: Orphan nuclear receptor RORgamma confers
doxorubicin resistance in prostate cancer. Cell Biol Int.
44:2170–2176. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang Z, Li Y, Wu D, Yu S, Wang Y and Chan
FL: Correction: Nuclear receptor HNF4α performs a tumor suppressor
function in prostate cancer via its induction of p21-driven
cellular senescence. Oncogene. 39:62632020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen J, Lin H, Li G, Jin RA, Shi L, Chen
M, Chang C and Cai X: TR4 nuclear receptor enhances the cisplatin
chemo-sensitivity via altering the ATF3 expression to better
suppress HCC cell growth. Oncotarget. 7:32088–32099. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shyr CR, Hu YC, Kim E and Chang C:
Modulation of estrogen receptor-mediated transactivation by orphan
receptor TR4 in MCF-7 cells. J Biol Chem. 277:14622–14628. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang L, Zhang J, Ma Y, Chen J, Dong B,
Zhao W, Wang X, Zheng Q, Fang F and Yang Y: Testicular orphan
receptor 4 (TR4) is a marker for metastasis and poor prognosis in
non-small cell lung cancer that drives the EMT phenotype. Lung
Cancer. 89:320–328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bai J, Yeh S, Qiu X, Hu L, Zeng J, Cai Y,
Zuo L, Li G, Yang G and Chang C: TR4 nuclear receptor promotes
clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM)
formation and metastasis via altering the miR490-3p/vimentin
signals. Oncogene. 37:5901–5912. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang M, Sun Y, Xu J, Lu J, Wang K, Yang
DR, Yang G, Li G and Chang C: Preclinical studies using miR-32-5p
to suppress clear cell renal cell carcinoma metastasis via altering
the miR-32-5p/TR4/HGF/Met signaling. Int J Cancer. 143:100–112.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin SJ, Lee SO, Lee YF, Miyamoto H, Yang
DR, Li G and Chang C: TR4 nuclear receptor functions as a tumor
suppressor for prostate tumorigenesis via modulation of DNA
damage/repair system. Carcinogenesis. 35:1399–1406. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ding X, Yang DR, Lee SO, Chen YL, Xia L,
Lin SJ, Yu S, Niu YJ, Li G and Chang C: TR4 nuclear receptor
promotes prostate cancer metastasis via upregulation of CCL2/CCR2
signaling. Int J Cancer. 136:955–964. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu S, Wang M, Ding X, Xia L, Chen B, Chen
Y, Zhang Z, Niu Y, Li G and Chang C: Testicular orphan nuclear
receptor 4 is associated with the radio-sensitivity of prostate
cancer. Prostate. 75:1632–1642. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen B, Yu S, Ding X, Jing C, Xia L, Wang
M, Matro E, Rehman F, Niu Y, Li G and Chang C: The role of
testicular nuclear receptor 4 in chemo-resistance of docetaxel in
castration-resistant prostate cancer. Cancer Gene Ther. 21:411–415.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li S, Wu X, Xu Y, Wu S, Li Z, Chen R,
Huang N, Zhu Z and Xu X: miR-145 suppresses colorectal cancer cell
migration and invasion by targeting an ETS-related gene. Oncol Rep.
36:1917–1926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li
D, Lai L and Jiang BH: miR-145 directly targets p70S6K1 in cancer
cells to inhibit tumor growth and angiogenesis. Nuclc Acids Res.
40:761–774. 2012. View Article : Google Scholar
|
|
47
|
Cho WC, Chow AS and Au JS: miR-145
inhibits cell proliferation of human lung adenocarcinoma by
targeting EGFR and NUDT1. RNA Biol. 8:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fuse M, Nohata N, Kojima S, Sakamoto S,
Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T
and Seki N: Restoration of miR-145 expression suppresses cell
proliferation, migration and invasion in prostate cancer by
targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.PubMed/NCBI
|
|
50
|
Gong P, Zhang T, He D and Hsieh JT:
MicroRNA-145 modulates tumor sensitivity to radiation in prostate
cancer. Radiat Res. 184:630–638. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Griesing S, Kajino T, Tai MC, Liu Z,
Nakatochi M, Shimada Y, Suzuki M and Takahashi T: Thyroid
transcription factor-1-regulated microRNA-532-5p targets KRAS and
MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
Cancer Sci. 108:1394–1404. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pan Q, Meng L, Ye J, Wei X, Shang Y, Tian
Y, He Y, Peng Z, Chen L, Chen W, et al: Transcriptional repression
of miR-200 family members by Nanog in colon cancer cells induces
epithelial-mesenchymal transition (EMT). Cancer Lett. 392:26–38.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
O'Geen H, Lin YH, Xu X, Echipare L,
Komashko VM, He D, Frietze S, Tanabe O, Shi L, Sartor MA, et al:
Genome-wide binding of the orphan nuclear receptor TR4 suggests its
general role in fundamental biological processes. BMC Genomics.
11:6892010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Larne O, Hagman Z, Lilja H, Bjartell A,
Edsjö A and Ceder Y: miR-145 suppress the androgen receptor in
prostate cancer cells and correlates to prostate cancer prognosis.
Carcinogenesis. 36:858–866. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li R, Azzollini D, Shen R, Thorup J,
Clasen-Linde E, Cortes D and Hutson JM: Postnatal germ cell
development during first 18 months of life in testes from boys with
non-syndromic cryptorchidism and complete or partial androgen
insensitivity syndrome. J Pediatr Surg. 54:1654–1659. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang J, Lu M, Qiu C and Cui Q: TransmiR: A
transcription factor-microRNA regulation database. Nucleic Acids
Res. 38((Database Issue)): D119–D122. 2010. View Article : Google Scholar : PubMed/NCBI
|
